POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2 (5α-Reductase Type II) GENES IN PROSTATE CANCER
İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4
*Corresponding Author: Muzeyyen İzmirli, Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, 34093, Istanbul, Turkey; Tel.: +90-212-523-37-19, Fax: +90-212-523-23-26; E-mail: muzeyyenizmirli@gmail.com.
page: 31

DISCUSSION

We found significant differences between the patient and control groups for Ser217Leu in the HPC2/ELAC2 gene and for Ala49Thr in the SRD5A2 gene. However, we did not see any difference between the patient and control groups for Ala541Thr in the HPC2/ ELAC2 gene and for Val89Leu in the SRD5A2 gene. There is controversy on the role of HPC2/ELAC2 and SRD5A2 genes in prostate cancer. They focus on different populations or populations from different regions in the same country. There are several studies which reveal that there is correlation between prostate cancer patients and their ethnic backgrounds. Some of the investigated populations were Caucasian, African-American, Asian, Canadian, American-Caucasians and British for the Ser217Leu polymorphism in the HPC2/ELAC2 gene [4,12,15]. Our findings in the Turkish population for the correlation between the Ser217Leu polymorphism in the HPC2/ELAC2 gene and prostate cancer risk agree with those of the above-mentioned studies. In contrast with those findings, no association was found between Ser217Leu polymorphism in the HPC2/ELAC2 gene in Finnish, Caucasian, African-American and American- Caucasian prostate cancer patients [16-18]. The other polymorphism is Ala541Thr for the HPC2/ ELAC2 gene which has been studied by a number of investigators for different populations. Some of these results for Canadian, Japanese, African-American and American-Caucasian and Asian populations were statistically significant [4,13,15,19]. However, some results of Caucasian, Finnish and British men with prostate cancer were not statistically significant which are in agreement with our findings [14,16,17]. There are a number of studies based on the investigation of different populations with the Ala49Thr polymorphism in the SRD5A2 gene. Some studies for African- American, Hispanic, Caucasians, French and American men [9,11,20,21] had similar results which indicates a significant difference between the Ala49Thr polymorphism in the SRD5A2 gene and prostate cancer patients. However, negative findings were reported by several studies about Chinese and Turkish populations [20,21]. In contrast, we showed significant differences between patients and controls regarding the Thr49 allele. In a previously published study, the Val89Leu polymorphism was investigated for Japanese, Indian, French, Caucasian, Chinese and Turkish populations. It has recently been shown that there was no correlation between the Val89Leu genotype and prostate cancer [9,21-23,26, 27]. Our results also support the findings of these studies based on the SRD5A2 gene in Turkish men with prostate cancer. According to statistical data, some of the screened populations were significantly different. They were Canadian, American and Caucasian populations [11,24,25]. However, Soderstrom et al. [28] published that the Leu89 allele decreased the risk of prostate cancer about 6.67-fold. In conclusion, genetic polymorphisms are affected by ethnic backgrounds. In order to reveal the correlation between some polymorphisms and prostate cancer, we investigated the Ser21Leu and Ala541Thr polymorphisms in the HPC2/ ELAC2 gene and Ala49Thr and Val89Leu polymorphisms in the SRD5A2 gene in a Turkish population with prostate cancer. We found correlations between the Ser217Leu and Ala49Thr polymorphisms and the disease according to our sample size. In order to get a certain result about the relation, larger samples are needed; depending on this, further studies may achieve the exact correlation.



Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Accepted articles
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Accepted articles
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006